NEURAXIS INC (NRXS) Fundamental Analysis & Valuation

NYSEARCA:NRXS • US64134X2018

Current stock price

7.3 USD
+0.69 (+10.44%)
Last:

This NRXS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. NRXS Profitability Analysis

1.1 Basic Checks

  • NRXS had negative earnings in the past year.
  • NRXS had a negative operating cash flow in the past year.
  • NRXS had negative earnings in each of the past 5 years.
  • NRXS had a negative operating cash flow in each of the past 5 years.
NRXS Yearly Net Income VS EBIT VS OCF VS FCFNRXS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -5M -10M

1.2 Ratios

  • NRXS's Return On Assets of -144.91% is on the low side compared to the rest of the industry. NRXS is outperformed by 86.17% of its industry peers.
  • NRXS has a Return On Equity of -366.35%. This is in the lower half of the industry: NRXS underperforms 79.79% of its industry peers.
Industry RankSector Rank
ROA -144.91%
ROE -366.35%
ROIC N/A
ROA(3y)-1140.93%
ROA(5y)-815%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NRXS Yearly ROA, ROE, ROICNRXS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 1K -1K -2K

1.3 Margins

  • NRXS has a better Gross Margin (84.33%) than 93.62% of its industry peers.
  • NRXS's Gross Margin has improved in the last couple of years.
  • The Profit Margin and Operating Margin are not available for NRXS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 84.33%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.51%
GM growth 5YN/A
NRXS Yearly Profit, Operating, Gross MarginsNRXS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. NRXS Health Analysis

2.1 Basic Checks

  • NRXS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • NRXS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NRXS Yearly Shares OutstandingNRXS Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2M 4M 6M
NRXS Yearly Total Debt VS Total AssetsNRXS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 1M 2M 3M 4M

2.2 Solvency

  • Based on the Altman-Z score of -6.51, we must say that NRXS is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of NRXS (-6.51) is worse than 73.94% of its industry peers.
  • NRXS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.51
ROIC/WACCN/A
WACC10.63%
NRXS Yearly LT Debt VS Equity VS FCFNRXS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 2M -2M -4M -6M

2.3 Liquidity

  • A Current Ratio of 1.58 indicates that NRXS should not have too much problems paying its short term obligations.
  • NRXS has a Current ratio of 1.58. This is in the lower half of the industry: NRXS underperforms 72.34% of its industry peers.
  • NRXS has a Quick Ratio of 1.55. This is a normal value and indicates that NRXS is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Quick ratio value of 1.55, NRXS perfoms like the industry average, outperforming 41.49% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.58
Quick Ratio 1.55
NRXS Yearly Current Assets VS Current LiabilitesNRXS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2M 4M 6M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. NRXS Growth Analysis

3.1 Past

EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.05%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%27.39%

3.2 Future

  • NRXS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 36.06% yearly.
  • NRXS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 132.78% yearly.
EPS Next Y41.03%
EPS Next 2Y36.06%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year146.31%
Revenue Next 2Y132.78%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

NRXS Yearly Revenue VS EstimatesNRXS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 5M 10M 15M
NRXS Yearly EPS VS EstimatesNRXS Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

Find the best growth stocksShow best growing peers

1

4. NRXS Valuation Analysis

4.1 Price/Earnings Ratio

  • NRXS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NRXS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NRXS Price Earnings VS Forward Price EarningsNRXS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NRXS Per share dataNRXS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

  • A more expensive valuation may be justified as NRXS's earnings are expected to grow with 36.06% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.06%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NRXS Dividend Analysis

5.1 Amount

  • No dividends for NRXS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NRXS Fundamentals: All Metrics, Ratios and Statistics

NEURAXIS INC

NYSEARCA:NRXS (3/31/2026, 10:50:57 AM)

7.3

+0.69 (+10.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-19
Earnings (Next)05-12
Inst Owners21.19%
Inst Owner Change94.36%
Ins Owners20.06%
Ins Owner Change0%
Market Cap77.75M
Revenue(TTM)N/A
Net Income(TTM)-8.37M
Analysts82.5
Price Target8.67 (18.77%)
Short Float %1.88%
Short Ratio1
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-21.81%
Min EPS beat(2)-38.41%
Max EPS beat(2)-5.21%
EPS beat(4)0
Avg EPS beat(4)-173.28%
Min EPS beat(4)-614.71%
Max EPS beat(4)-5.21%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-15.65%
Min Revenue beat(2)-20.45%
Max Revenue beat(2)-10.86%
Revenue beat(4)0
Avg Revenue beat(4)-52.65%
Min Revenue beat(4)-99.88%
Max Revenue beat(4)-10.86%
Revenue beat(8)0
Avg Revenue beat(8)-63.31%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)21.43%
PT rev (3m)44.68%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-4.71%
EPS NY rev (3m)-1.01%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 23.12
P/FCF N/A
P/OCF N/A
P/B 34.02
P/tB 38.84
EV/EBITDA N/A
EPS(TTM)-0.96
EYN/A
EPS(NY)-0.57
Fwd EYN/A
FCF(TTM)-0.59
FCFYN/A
OCF(TTM)-0.59
OCFYN/A
SpS0.32
BVpS0.21
TBVpS0.19
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -144.91%
ROE -366.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 84.33%
FCFM N/A
ROA(3y)-1140.93%
ROA(5y)-815%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.51%
GM growth 5YN/A
F-Score4
Asset Turnover0.58
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 59.81%
Cap/Sales 0.75%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.58
Quick Ratio 1.55
Altman-Z -6.51
F-Score4
WACC10.63%
ROIC/WACCN/A
Cap/Depr(3y)133.32%
Cap/Depr(5y)94.99%
Cap/Sales(3y)2.06%
Cap/Sales(5y)1.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.05%
EPS Next Y41.03%
EPS Next 2Y36.06%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%27.39%
Revenue Next Year146.31%
Revenue Next 2Y132.78%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-3.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1096.17%
EBIT Next 3Y-16.84%
EBIT Next 5YN/A
FCF growth 1Y-43.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-46.19%
OCF growth 3YN/A
OCF growth 5YN/A

NEURAXIS INC / NRXS Fundamental Analysis FAQ

What is the fundamental rating for NRXS stock?

ChartMill assigns a fundamental rating of 3 / 10 to NRXS.


Can you provide the valuation status for NEURAXIS INC?

ChartMill assigns a valuation rating of 1 / 10 to NEURAXIS INC (NRXS). This can be considered as Overvalued.


What is the profitability of NRXS stock?

NEURAXIS INC (NRXS) has a profitability rating of 1 / 10.